細胞穿透胜肽市場機會、成長促進因素、產業趨勢分析與預測 2024 - 2032

Cell Penetrating Peptide Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年10月17日 | 出版商:

Global Market Insights Inc. | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球細胞穿透胜肽市場估值為19 億美元，預計2024 年至2032 年複合年成長率將強勁成長12.9%。成長，如CPP具有將治療劑直接輸送到細胞的獨特能力。透過增強藥物、蛋白質和遺傳物質向特定細胞標靶的輸送，CPP 可以提高治療效果，同時最大限度地減少潛在的副作用，這使得它們對於精準醫療特別有價值。細胞穿透胜肽是短鏈胺基酸，通常有 5 到 30 個殘基，可以有效地穿過細胞膜。這些胜肽促進多種生物分子的細胞內遞送，包括蛋白質、核酸和小型治療化合物，而不會對細胞造成顯著傷害。

它們採用多種細胞進入機制，包括胞吞作用和直接易位，這導致了對其在藥物傳輸、基因治療和各種生物醫學領域的應用的廣泛研究。 CPP 市場可依類型分為合成胜肽、蛋白質衍生胜肽和嵌合胜肽。 2023年，合成材料領域引領市場，佔8.809億美元。與天然或蛋白質衍生的對應物相比，合成 CPP 具有卓越的穩定性，可以更好地控制尺寸、電荷和疏水性等特性。

這種設計靈活性使它們非常適合各種藥物傳輸應用，特別是在具有挑戰性的生理條件下。在考慮應用時，藥物傳輸領域在 2023 年佔據最大的市場佔有率，達到 30.7%。 CPP 在將治療藥物直接遞送至指定細胞或組織方面特別有效，可提高治療精確度，同時減少脫靶效應。這種能力對於需要標靶治療的疾病特別有益，因為它可以顯著改善治療結果並減少毒性。

市場範圍
開始年份	2023年
預測年份	2024-2032
起始值	19億美元
預測值	57 億美元
複合年成長率	12.9%

北美將在2023 年成為最大的細胞穿透胜肽市場，產生7.37 億美元的收入，預計到2032 年將達到21 億美元。和應用遞送和基因治療。此外，對個人化醫療的大量投資以及基因編輯技術的進步，增加了對有效細胞內遞送系統的需求，其中 CPP 有助於影響細胞屏障。

The Global Cell Penetrating Peptide Market was valued at USD 1.9 billion in 2023, with projections indicating a robust growth rate of 12.9% CAGR from 2024 to 2032. A key driver of this market expansion is the increasing demand for targeted drug delivery systems, as CPPs possess a unique capability to transport therapeutic agents directly into cells. By enhancing the delivery of drugs, proteins, and genetic materials to specific cellular targets, CPPs improve therapeutic effectiveness while minimizing potential side effects, making them particularly valuable for precision medicine. Cell-penetrating peptides are short chains of amino acids, typically ranging from 5 to 30 residues, that can effectively traverse cellular membranes. These peptides facilitate the intracellular delivery of a variety of biomolecules, including proteins, nucleic acids, and small therapeutic compounds, without causing significant harm to the cells.

They employ several mechanisms for cellular entry, including endocytosis and direct translocation, which has led to extensive research into their applications in drug delivery, gene therapy, and various biomedical fields. The market for CPPs can be categorized by type into synthetic, protein-derived, and chimeric peptides. In 2023, the synthetic segment led the market, accounting for USD 880.9 million. Synthetic CPPs provide superior stability compared to their natural or protein-derived counterparts, offering better control over properties such as size, charge, and hydrophobicity.

This design flexibility makes them well-suited for diverse drug delivery applications, particularly in challenging physiological conditions. When considering applications, the drug delivery sector held the largest market share in 2023, at 30.7%. CPPs are particularly effective in delivering therapeutic agents directly to designated cells or tissues, enhancing treatment precision while reducing off-target effects. This capability is especially beneficial for conditions requiring targeted therapies, as it can significantly improve treatment outcomes and reduce toxicity.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$1.9 Billion
Forecast Value	$5.7 Billion
CAGR	12.9%

North America emerged as the largest market for cell-penetrating peptides in 2023, generating USD 737 million in revenue and projected to reach USD 2.1 billion by 2032. The region's robust presence of biopharmaceutical firms and research organizations fuels the development and application of CPPs in drug delivery and gene therapy. Additionally, significant investments in personalized medicine, along with advancements in gene editing technologies, have heightened the demand for effective intracellular delivery systems, where CPPs help affect cellular barriers.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising demand for targeted drug delivery
  - 3.2.1.2 Advancements in biotechnology
  - 3.2.1.3 Technological innovations
  - 3.2.1.4 Increased focus on personalized medicine
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High production costs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technology landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Protein-derived
5.3 Synthetic
5.4 Chimeric

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Drug delivery
6.3 Gene delivery
6.4 Diagnostics
6.5 Molecular imaging
6.6 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Pharmaceutical and biotechnology companies
7.3 Contract research organizations (CROs)
7.4 Hospitals and clinics
7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE